Compare · ACOR vs GILD
ACOR vs GILD
Side-by-side comparison of Acorda Therapeutics Inc. (ACOR) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACOR and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $160.55B, about 8097.0x ACOR ($19.8M).
- GILD has hit the wire 7 times in the past 4 weeks while ACOR has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for ACOR).
- Company
- Acorda Therapeutics Inc.
- Gilead Sciences Inc.
- Price
- $0.66-21.00%
- $129.35-1.16%
- Market cap
- $19.8M
- $160.55B
- 1M return
- -
- +3.36%
- 1Y return
- -
- +11.31%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- 1992
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 25
Acorda Therapeutics Inc.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ACOR
- Flow Sciences Appoints Michael Gesser as Chief Financial Officer
- SEC Form 10-Q filed by Acorda Therapeutics Inc.
- SEC Form 10-K/A filed by Acorda Therapeutics Inc. (Amendment)
- Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Acorda Therapeutics Reports Delisting From Nasdaq
- Acorda Therapeutics Announces Delisting from Nasdaq
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
Latest GILD
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
- Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Gilead Sciences downgraded by Leerink Partners with a new price target
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors